Predictmedix Inc.

Predictmedix Inc., an artificial intelligence (AI) company, develops AI powered technologies for general workplace health and safety, and health care industry. The company operates in two segments, Workplace Health and Safety, and Healthcare. It offers disease symptom screening solutions to identify persons who are more likely to test positive for infectious diseases and to undergo a definitive test, such as a rapid COVID test. The company also develops impairment detection screening scanners and mental health screening stations; and Mobile Wellbeing, a telemedicine remote patient monitoring platform. The company was formerly known as Cultivar Holdings Inc. and changed its name to Predictmedix Inc. in April 2020. Predictmedix Inc. is headquartered in Toronto, Canada.

Predictmedix Inc. trades as PMED.CN on CNQ. The company is classified in Healthcare / Medical - Devices and reports in CAD.

The current profile places the business in Medical - Devices. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows $0 of revenue and -$1.18M of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Predictmedix Inc. can be compared against peers such as AI/ML Innovations Inc., Ayurcann Holdings Corp., BioVaxys Technology Corp., CLS Holdings USA, Inc., Diagnamed Holdings Corp., Glow Lifetech Corp..

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $11.37M, beta of 1.90, and return on equity of +89.1%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

PMED.CN currently shows total debt of $0 and beta of 1.90. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.predictmedix.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.